We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

USPTO Grants Two New Patents to Metabolon

USPTO Grants Two New Patents to Metabolon

USPTO Grants Two New Patents to Metabolon

USPTO Grants Two New Patents to Metabolon

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "USPTO Grants Two New Patents to Metabolon"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Metabolon, Inc., the leader in metabolomics, biomarker discovery and biochemical analysis, has announced that it was awarded two new US Patents.

With the grant of these patents Metabolon currently holds 17 US Patents related to its biochemical profiling methods, data analysis solutions and biomarkers for disease and toxicity.

US Patent 7,947,453 “Methods for Drug Discovery, Disease Treatment and Diagnosis Using Metabolomics” was granted by the United States Patent and Trademark Office on May 24, 2011. It is the tenth patent to issue from the fundamental Daouk-Kristal “metabolomics methods” patent family.

The ‘453 patent provides a method to predict an individual’s drug response, thereby facilitating personalized medical treatment, such as for cancer chemotherapy, and treatments for metabolic disorders and depression.

US Patent 7,9490,475 “System and Method for Analyzing Metabolomic Data” was also granted by the USPTO on May 24, 2011. The ‘475 patent provides a unique visual display of metabolomic data generated by multiple analytical platforms, including GC-MS and LC-MS, and MS/MS.

With this technology Metabolon scientists are able to simultaneously evaluate a series of raw and complex data sets in a single comprehensive visual display. It is a critical component of Metabolon’s ability to quickly identify compounds with high confidence and identify biomarkers.

"These patents support our intellectual property strategy for our biomarker and biochemical analysis program, which will aid in predicting drug responses in individuals and identifying disease biomarkers for more personalized treatment," said John Ryals, Metabolon president and CEO.

Ryals continued, “With 17 issued US patents broadly covering metabolomics methods and software, Metabolon has assembled the dominant IP position in the field of metabolomics.”

Metabolon is the exclusive license holder of the Daouk-Kristal patent family which is comprised of early, pioneering patents and patent applications which provide fundamental IP in the field of metabolomics.

Metabolon’s previously issued patents include the use of metabolomics for determining biomarkers for disease, including cancer, metabolic disorders, and neurological disorders such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, depression and schizophrenia.

Metabolon also owns patents relating to disease biomarkers and for software designed for analyzing metabolomics data.